• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发缓解型和原发进展型多发性硬化症发病相关的危险因素:一项系统综述。

Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review.

作者信息

McKay Kyla A, Kwan Vivian, Duggan Thomas, Tremlett Helen

机构信息

Faculty of Medicine (Neurology), Vancouver Coastal Health Research Institute, Brain Research Centre, University of British Columbia, Vancouver, BC, Canada V6T 2B5.

出版信息

Biomed Res Int. 2015;2015:817238. doi: 10.1155/2015/817238. Epub 2015 Jan 31.

DOI:10.1155/2015/817238
PMID:25802867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4329850/
Abstract

Multiple sclerosis (MS) is a chronic central nervous system disease with a highly heterogeneous course. The aetiology of MS is not well understood but is likely a combination of both genetic and environmental factors. Approximately 85% of patients present with relapsing-remitting MS (RRMS), while 10-15% present with primary progressive MS (PPMS). PPMS is associated with an older onset age, a different sex ratio, and a considerably more rapid disease progression relative to RRMS. We systematically reviewed the literature to identify modifiable risk factors that may be associated with these different clinical courses. We performed a search of six databases and integrated twenty observational studies into a descriptive review. Exposure to Epstein-Barr virus (EBV) appeared to increase the risk of RRMS, but its association with PPMS was less clear. Other infections, such as human herpesvirus-6 and chlamydia pneumoniae, were not consistently associated with a specific disease course nor was cigarette smoking. Despite the vast literature examining risk factors for the development of MS, relatively few studies reported findings by disease course. This review exposes a gap in our understanding of the risk factors associated with the onset of PPMS, our current knowledge being predominated by relapsing-onset MS.

摘要

多发性硬化症(MS)是一种病程高度异质性的慢性中枢神经系统疾病。MS的病因尚不完全清楚,但可能是遗传和环境因素共同作用的结果。约85%的患者表现为复发缓解型多发性硬化症(RRMS),而10 - 15%的患者表现为原发进展型多发性硬化症(PPMS)。与RRMS相比,PPMS发病年龄较大,性别比例不同,疾病进展明显更快。我们系统回顾了文献,以确定可能与这些不同临床病程相关的可改变风险因素。我们检索了六个数据库,并将20项观察性研究纳入描述性综述。感染爱泼斯坦 - 巴尔病毒(EBV)似乎会增加RRMS的风险,但其与PPMS的关联尚不清楚。其他感染,如人类疱疹病毒6型和肺炎衣原体,以及吸烟,均未始终与特定病程相关。尽管有大量关于MS发病风险因素的文献,但相对较少的研究按病程报告结果。本综述揭示了我们对与PPMS发病相关风险因素的理解存在差距,目前我们的认知主要基于复发型MS。

相似文献

1
Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review.复发缓解型和原发进展型多发性硬化症发病相关的危险因素:一项系统综述。
Biomed Res Int. 2015;2015:817238. doi: 10.1155/2015/817238. Epub 2015 Jan 31.
2
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.用于多发性硬化症的免疫调节剂和免疫抑制剂:一项网状Meta分析
Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD008933. doi: 10.1002/14651858.CD008933.pub2.
3
Azathioprine for people with multiple sclerosis.硫唑嘌呤用于多发性硬化症患者。
Cochrane Database Syst Rev. 2024 Dec 9;12(12):CD015005. doi: 10.1002/14651858.CD015005.pub2.
4
Rituximab for relapsing-remitting multiple sclerosis.利妥昔单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
5
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3.
6
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.免疫调节剂和免疫抑制剂治疗复发缓解型多发性硬化症的网状 Meta 分析。
Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD011381. doi: 10.1002/14651858.CD011381.pub3.
7
Natalizumab for relapsing remitting multiple sclerosis.那他珠单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD007621. doi: 10.1002/14651858.CD007621.pub2.
8
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.用于复发缓解型多发性硬化症的免疫调节剂和免疫抑制剂:一项网状荟萃分析。
Cochrane Database Syst Rev. 2015 Sep 18;2015(9):CD011381. doi: 10.1002/14651858.CD011381.pub2.
9
Relevance of choroid plexus volumes in multiple sclerosis.脉络丛体积在多发性硬化症中的相关性。
Fluids Barriers CNS. 2025 May 8;22(1):47. doi: 10.1186/s12987-025-00656-7.
10
Fingolimod for relapsing-remitting multiple sclerosis.芬戈莫德用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2016 Apr 19;4(4):CD009371. doi: 10.1002/14651858.CD009371.pub2.

引用本文的文献

1
The Role of MRI Lesions in Identifying Secondary Progressive Multiple Sclerosis: A Comprehensive Review.MRI病变在识别继发进展型多发性硬化中的作用:一项综述
J Clin Med. 2025 Jun 10;14(12):4114. doi: 10.3390/jcm14124114.
2
Influence of race and gender on variability in clinical decision-making in neurology.种族和性别对神经病学临床决策变异性的影响。
Sci Rep. 2025 May 23;15(1):17882. doi: 10.1038/s41598-025-00726-8.
3
Machine learning for refining interpretation of magnetic resonance imaging scans in the management of multiple sclerosis: a narrative review.机器学习在多发性硬化症管理中优化磁共振成像扫描解读的应用:一项叙述性综述
R Soc Open Sci. 2025 Jan 22;12(1):241052. doi: 10.1098/rsos.241052. eCollection 2025 Jan.
4
Integrated Transcriptome Analysis Reveals Molecular Subtypes and ceRNA Networks in Multiple Sclerosis.综合转录组分析揭示多发性硬化症的分子亚型和ceRNA网络。
Degener Neurol Neuromuscul Dis. 2024 Dec 21;14:115-130. doi: 10.2147/DNND.S491211. eCollection 2024.
5
Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis.蛋白质组学揭示年龄是多发性硬化症炎症性 CSF 特征的主要修饰因子。
Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200322. doi: 10.1212/NXI.0000000000200322. Epub 2024 Nov 13.
6
The Probable Infectious Origin of Multiple Sclerosis.多发性硬化症可能的感染起源
NeuroSci. 2023 Sep 7;4(3):211-234. doi: 10.3390/neurosci4030019. eCollection 2023 Sep.
7
Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.多奈哌齐治疗中重度阿尔茨海默病患者的疗效及安全性的多中心、随机、双盲、安慰剂平行对照临床研究
Clin Drug Investig. 2024 Nov;44(11):829-838. doi: 10.1007/s40261-024-01397-5. Epub 2024 Oct 28.
8
Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.从一个超过6000人的澳大利亚多发性硬化症(MS)患者大队列中估计残疾严重程度分类、MS表型和疾病修正治疗分类变化的转移概率。
Pharmacoeconomics. 2025 Feb;43(2):223-239. doi: 10.1007/s40273-024-01417-4. Epub 2024 Aug 2.
9
The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis.芬戈莫德与干扰素对控制多发性硬化症患者残疾及复发率的疗效:一项系统评价与荟萃分析
Int J Prev Med. 2024 Jan 30;14:131. doi: 10.4103/ijpvm.ijpvm_12_22. eCollection 2023.
10
Risk Factors for Relapsing Remitting Multiple Sclerosis.复发缓解型多发性硬化症的危险因素。
Br J Neurosci Nurs. 2021 Jan;17(Sup1):S34-S36. doi: 10.12968/bjnn.2021.17.Sup1.S34. Epub 2021 Jan 28.

本文引用的文献

1
Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review.与多发性硬化症的发病、复发或进展相关的因素:系统评价。
Neurotoxicology. 2017 Jul;61:189-212. doi: 10.1016/j.neuro.2016.03.020. Epub 2016 Apr 1.
2
Defining the clinical course of multiple sclerosis: the 2013 revisions.多发性硬化症临床病程的定义:2013年修订版
Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.
3
Incidence and prevalence of multiple sclerosis in Europe: a systematic review.欧洲多发性硬化症的发病率和患病率:系统评价。
BMC Neurol. 2013 Sep 26;13:128. doi: 10.1186/1471-2377-13-128.
4
Epstein-Barr virus in oral shedding of children with multiple sclerosis.儿童多发性硬化症口腔排毒中的 EBV。
Neurology. 2013 Oct 15;81(16):1392-9. doi: 10.1212/WNL.0b013e3182a841e4. Epub 2013 Sep 6.
5
Torque teno virus (TTV) in multiple sclerosis patients with different patterns of disease.多灶性硬化症患者不同疾病模式中的扭体病毒(TTV)。
J Med Virol. 2013 Dec;85(12):2176-83. doi: 10.1002/jmv.23707. Epub 2013 Aug 19.
6
Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study.吸烟与多发性硬化症残疾进展的关系:英国队列研究。
Brain. 2013 Jul;136(Pt 7):2298-304. doi: 10.1093/brain/awt139. Epub 2013 Jun 11.
7
Confounding underlies the apparent month of birth effect in multiple sclerosis.混杂因素导致多发性硬化症中出生月份的明显效应。
Ann Neurol. 2013 Jun;73(6):714-20. doi: 10.1002/ana.23925. Epub 2013 Jul 2.
8
Evaluation of reactive Epstein-Barr Virus (EBV) in Iranian patient with different subtypes of multiple sclerosis (MS).评价不同亚型多发性硬化症(MS)伊朗患者中的反应性 Epstein-Barr 病毒(EBV)。
Braz J Infect Dis. 2013 Mar-Apr;17(2):156-63. doi: 10.1016/j.bjid.2012.09.008. Epub 2013 Mar 5.
9
Incidence and prevalence of multiple sclerosis in the Americas: a systematic review.美洲多发性硬化症的发病率和患病率:系统评价。
Neuroepidemiology. 2013;40(3):195-210. doi: 10.1159/000342779. Epub 2013 Jan 24.
10
Month of birth as a risk factor for multiple sclerosis: an update.出生月份作为多发性硬化症的一个风险因素:最新情况
Acta Neurol Scand Suppl. 2012(195):58-62. doi: 10.1111/ane.12040.